| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e82f8e464d5aa52560f1ea2f42e438b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9450d9aac786b86a8b6ae4c6832fdc62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e73ce7e85022b47d4d8d4ed5025fc93e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02cf545f23bafb54fb0a155aee310783 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-10132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-10111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-10161 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2002-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f6a750c38f5b71c6add458e9769c3fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddec7ba6b53de97c2bfd591e7f511603
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c75feddbf49e8dfcc182937bef349315 |
| publicationDate |
2003-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03026767-A2 |
| titleOfInvention |
Lysin-deficient bacteriophages having reduced immunogenicity |
| abstract |
The present invention features therapeutic bacteriophage deficient in the lysin protein ('Lys minus' phage). Lys minus bacteriophage are incapable of facilitating efficient lysis of the bacterial host since the enzymatic activity of the lysin of the phage is needed for breaking down the peptidoglycan layer of the bacterial cell wall. Lys minus bacteriophage retain activity in invasion of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. Therefore, the therapeutic Lys minus phage stops the spread of infection by the bacterial pathogen without lysis of the bacterium. This approach is attractive as it also prevents the release of the phage progeny, thus reducing or eliminating the potential for generation of immune responses against the phage. The incapacitated bacterial pathogen is then removed by the normal defense systems such as phagocytes and macrophages. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2544957-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005508912-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7087226-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2544957-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010180227-A |
| priorityDate |
2001-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |